RxSight Gestione
Gestione criteri di controllo 3/4
RxSight Il CEO è Ron Kurtz, nominato in Jan2016, e ha un mandato di 8.92 anni. la retribuzione annua totale è $ 3.08M, composta da 20.6% di stipendio e 79.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.05% delle azioni della società, per un valore di $ 37.96M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.2 anni e 3.3 anni.
Informazioni chiave
Ron Kurtz
Amministratore delegato
US$3.1m
Compenso totale
| Percentuale dello stipendio del CEO | 20.6% |
| Mandato del CEO | 8.9yrs |
| Proprietà del CEO | 2.1% |
| Durata media del management | 4.2yrs |
| Durata media del Consiglio di amministrazione | 3.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$31m |
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$3m | US$633k | -US$49m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$1m | US$563k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$67m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$5m | US$445k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | US$17m |
| Dec 31 2020 | US$741k | US$310k | US$3m |
Compensazione vs Mercato: La retribuzione totale di Ron ($USD 3.08M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.36M ).
Compensazione vs guadagni: La retribuzione di Ron è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Ron Kurtz (61 yo)
8.9yrs
Mandato
US$3,081,597
Compensazione
Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as President and Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 20...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 8.9yrs | US$3.08m | 2.05% $ 38.0m | |
| Co-President & Chief Commercial Officer | 9.5yrs | US$1.65m | 0.76% $ 14.1m | |
| Co-President & Chief Financial Officer | 7.8yrs | US$1.89m | 0.076% $ 1.4m | |
| Co-President & Chief Operating Officer | 5.5yrs | US$1.89m | 0.11% $ 2.0m | |
| Vice President of Accounting & Finance | no data | Nessun dato | Nessun dato | |
| Chief Technology Officer | no data | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | 1.1yrs | Nessun dato | Nessun dato | |
| Senior VP of Sales of North America | less than a year | Nessun dato | Nessun dato | |
| Senior VP of Marketing & Professional Relations | 2.9yrs | Nessun dato | Nessun dato | |
| Vice President of Human Resources | 9.3yrs | Nessun dato | Nessun dato | |
| Executive VP of Manufacturing & Commercial Operations | 2.9yrs | Nessun dato | Nessun dato | |
| Executive VP of Clinical & Regulatory Affairs | 2.8yrs | Nessun dato | Nessun dato |
4.2yrs
Durata media
62yo
Età media
Gestione esperta: Il team dirigenziale di RXST è considerato esperto (durata media dell'incarico 4.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 8.8yrs | US$3.08m | 2.05% $ 38.0m | |
| Director | 8.1yrs | US$204.98k | 0.11% $ 2.1m | |
| Independent Director | 3.3yrs | US$209.98k | 0.062% $ 1.2m | |
| Independent Director | 9.5yrs | US$209.98k | 0.090% $ 1.7m | |
| Independent Chairman of the Board | 9.9yrs | US$257.48k | 1.33% $ 24.6m | |
| Independent Director | 2.9yrs | US$204.98k | 0.057% $ 1.0m | |
| Independent Director | 3.3yrs | US$214.98k | 0.062% $ 1.2m | |
| Independent Director | 3.3yrs | US$212.48k | 0.062% $ 1.2m | |
| Independent Director | 3yrs | US$199.98k | 0.0048% $ 89.4k |
3.3yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RXST sono considerati esperti (durata media dell'incarico 3.3 anni).